Victoria L. Seewaldt, M.D., is a Professor of Medicine at Duke University where she leads the Duke University Comprehensive Cancer Breast and Ovarian Cancer Program. Dr. Seewaldt received her undergraduate degree from Cornell University in Chemistry. She worked for the late Henry Kaplan, M.D. before starting medical school at University of California at Davis in 1986. Dr. Seewaldt was an Intern OB/Gyn and Resident in Internal Medicine at University of Washington. She completed her residency and clinical Fellowship in Medical Oncology under the ABIM Clinical Investigator Pathway at University of Washington in 1993. From 1993 to 1998, Dr. Seewaldt was a Postdoctoral Fellow at Fred Hutchinson Cancer Research Center. Dr. Seewaldt was appointed as an Assistant Professor at Duke University in 2000. She was promoted to Associate Professor in 2003 and received Tenure in 2006. Dr. Seewaldt’s translational research involves multi-disciplinary, multi-institutional collaborations with basic, translational, and clinical scientists, with the goal of integrating novel functional imaging strategies with genetic and epigenetic markers of short-term breast cancer risk. The unique feature of Dr. Seewaldt’s program is that biomarkers identified in the laboratory can be immediately tested as predictors of short-term breast cancer risk in the high-risk women who participate in her cohort. Dr. Seewaldt sees her cohort as a resource for developing partnerships between clinical investigators and bioengineers to develop novel strategies for early detection.
The Rivkin Center strives for excellence in our scientific programming. Our Scientific Advisory board guides the work we do and helps shape our vision for the future of ovarian cancer research. The Board is led by Dr. Mary L. (Nora) Disis, MD, our Scientific and Medical Director, and consists of nationally recognized experts in ovarian cancer research.